Mechanism Study of Prussian Blue Nanozymes in the Treatment of Crohn's Disease Based on Metagenomic Analysis

Crohn's Disease (CD) is a type of inflammatory bowel disease (IBD) with an unknown etiology, characterized by gastrointestinal immune-related inflammation. Currently, there is no specific drug for treating IBD, and existing treatments only alleviate symptoms with significant side effects that vary among individuals. Numerous studies have shown a close relationship between gut microbiota and Crohn's disease. However, due to the unclear pathogenesis of Crohn's disease, microbial-based therapies have not been widely adopted. In this study, we used a TNBS (2, 4, 6-trinitrobenzene sulfonic acid)-induced rat model of Crohn's disease to treat the model group with Prussian Blue Nanozymes (PB). Based on metagenomic analysis, we examined the diversity, community changes, and species differences in gut microbiota before and after treatment, identifying 20 disease-related species, 16 PB treatment-related species, and significant community changes. This provides insights for further understanding the pathogenesis of Crohn's disease and the therapeutic mechanisms of Prussian Blue Nanozymes.